These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

260 related items for PubMed ID: 30814254

  • 1. Crystal structure of the WFIKKN2 follistatin domain reveals insight into how it inhibits growth differentiation factor 8 (GDF8) and GDF11.
    McCoy JC, Walker RG, Murray NH, Thompson TB.
    J Biol Chem; 2019 Apr 19; 294(16):6333-6343. PubMed ID: 30814254
    [Abstract] [Full Text] [Related]

  • 2. Structural basis for potency differences between GDF8 and GDF11.
    Walker RG, Czepnik M, Goebel EJ, McCoy JC, Vujic A, Cho M, Oh J, Aykul S, Walton KL, Schang G, Bernard DJ, Hinck AP, Harrison CA, Martinez-Hackert E, Wagers AJ, Lee RT, Thompson TB.
    BMC Biol; 2017 Mar 03; 15(1):19. PubMed ID: 28257634
    [Abstract] [Full Text] [Related]

  • 3. Both WFIKKN1 and WFIKKN2 have high affinity for growth and differentiation factors 8 and 11.
    Kondás K, Szláma G, Trexler M, Patthy L.
    J Biol Chem; 2008 Aug 29; 283(35):23677-84. PubMed ID: 18596030
    [Abstract] [Full Text] [Related]

  • 4. Relationships of GDF8 and 11 and Their Antagonists With Decline of Grip Strength Among Older Adults in the Baltimore Longitudinal Study of Aging.
    Yamaguchi Y, Zhu M, Moaddel R, Palchamy E, Ferrucci L, Semba RD.
    J Gerontol A Biol Sci Med Sci; 2023 Oct 09; 78(10):1793-1798. PubMed ID: 37235639
    [Abstract] [Full Text] [Related]

  • 5. Relationship of Circulating Growth and Differentiation Factors 8 and 11 and Their Antagonists as Measured Using Liquid Chromatography-Tandem Mass Spectrometry With Age and Skeletal Muscle Strength in Healthy Adults.
    Semba RD, Zhang P, Zhu M, Fabbri E, Gonzalez-Freire M, Carlson OD, Moaddel R, Tanaka T, Egan JM, Ferrucci L.
    J Gerontol A Biol Sci Med Sci; 2019 Jan 01; 74(1):129-136. PubMed ID: 30380014
    [Abstract] [Full Text] [Related]

  • 6. WFIKKN1 and WFIKKN2 bind growth factors TGFβ1, BMP2 and BMP4 but do not inhibit their signalling activity.
    Szláma G, Kondás K, Trexler M, Patthy L.
    FEBS J; 2010 Dec 01; 277(24):5040-50. PubMed ID: 21054789
    [Abstract] [Full Text] [Related]

  • 7. Differential antagonism of activin, myostatin and growth and differentiation factor 11 by wild-type and mutant follistatin.
    Schneyer AL, Sidis Y, Gulati A, Sun JL, Keutmann H, Krasney PA.
    Endocrinology; 2008 Sep 01; 149(9):4589-95. PubMed ID: 18535106
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Crystal structure of human GDF11.
    Padyana AK, Vaidialingam B, Hayes DB, Gupta P, Franti M, Farrow NA.
    Acta Crystallogr F Struct Biol Commun; 2016 Mar 01; 72(Pt 3):160-4. PubMed ID: 26919518
    [Abstract] [Full Text] [Related]

  • 10. Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation.
    Walker RG, Poggioli T, Katsimpardi L, Buchanan SM, Oh J, Wattrus S, Heidecker B, Fong YW, Rubin LL, Ganz P, Thompson TB, Wagers AJ, Lee RT.
    Circ Res; 2016 Apr 01; 118(7):1125-41; discussion 1142. PubMed ID: 27034275
    [Abstract] [Full Text] [Related]

  • 11. A targeted proteomic assay for the measurement of plasma proteoforms related to human aging phenotypes.
    Semba RD, Zhang P, Zhu M, Fabbri E, Gonzalez-Freire M, Moaddel R, Geng-Spyropoulos M, Ferrucci L.
    Proteomics; 2017 Aug 01; 17(15-16):. PubMed ID: 28508553
    [Abstract] [Full Text] [Related]

  • 12. Characterization of follistatin-type domains and their contribution to myostatin and activin A antagonism.
    Cash JN, Angerman EB, Keutmann HT, Thompson TB.
    Mol Endocrinol; 2012 Jul 01; 26(7):1167-78. PubMed ID: 22593183
    [Abstract] [Full Text] [Related]

  • 13. Functional substitutions of amino acids that differ between GDF11 and GDF8 impact skeletal development and skeletal muscle.
    Lian J, Walker RG, D'Amico A, Vujic A, Mills MJ, Messemer KA, Mendello KR, Goldstein JM, Leacock KA, Epp S, Stimpfl EV, Thompson TB, Wagers AJ, Lee RT.
    Life Sci Alliance; 2023 Mar 01; 6(3):. PubMed ID: 36631218
    [Abstract] [Full Text] [Related]

  • 14. WFIKKN1 and WFIKKN2: "Companion" proteins regulating TGFB activity.
    Monestier O, Blanquet V.
    Cytokine Growth Factor Rev; 2016 Dec 01; 32():75-84. PubMed ID: 27325460
    [Abstract] [Full Text] [Related]

  • 15. GDF11 promotes osteogenesis as opposed to MSTN, and follistatin, a MSTN/GDF11 inhibitor, increases muscle mass but weakens bone.
    Suh J, Kim NK, Lee SH, Eom JH, Lee Y, Park JC, Woo KM, Baek JH, Kim JE, Ryoo HM, Lee SJ, Lee YS.
    Proc Natl Acad Sci U S A; 2020 Mar 03; 117(9):4910-4920. PubMed ID: 32071240
    [Abstract] [Full Text] [Related]

  • 16. Regulation of GDF-11 and myostatin activity by GASP-1 and GASP-2.
    Lee YS, Lee SJ.
    Proc Natl Acad Sci U S A; 2013 Sep 24; 110(39):E3713-22. PubMed ID: 24019467
    [Abstract] [Full Text] [Related]

  • 17. Blockade of activin type II receptors with a dual anti-ActRIIA/IIB antibody is critical to promote maximal skeletal muscle hypertrophy.
    Morvan F, Rondeau JM, Zou C, Minetti G, Scheufler C, Scharenberg M, Jacobi C, Brebbia P, Ritter V, Toussaint G, Koelbing C, Leber X, Schilb A, Witte F, Lehmann S, Koch E, Geisse S, Glass DJ, Lach-Trifilieff E.
    Proc Natl Acad Sci U S A; 2017 Nov 21; 114(47):12448-12453. PubMed ID: 29109273
    [Abstract] [Full Text] [Related]

  • 18. Structure of myostatin·follistatin-like 3: N-terminal domains of follistatin-type molecules exhibit alternate modes of binding.
    Cash JN, Angerman EB, Kattamuri C, Nolan K, Zhao H, Sidis Y, Keutmann HT, Thompson TB.
    J Biol Chem; 2012 Jan 06; 287(2):1043-53. PubMed ID: 22052913
    [Abstract] [Full Text] [Related]

  • 19. A GDF11/myostatin inhibitor, GDF11 propeptide-Fc, increases skeletal muscle mass and improves muscle strength in dystrophic mdx mice.
    Jin Q, Qiao C, Li J, Xiao B, Li J, Xiao X.
    Skelet Muscle; 2019 May 27; 9(1):16. PubMed ID: 31133057
    [Abstract] [Full Text] [Related]

  • 20. Latent myostatin has significant activity and this activity is controlled more efficiently by WFIKKN1 than by WFIKKN2.
    Szláma G, Trexler M, Patthy L.
    FEBS J; 2013 Aug 27; 280(16):3822-39. PubMed ID: 23829672
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.